{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:59:21Z","timestamp":1698721161358},"reference-count":0,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[1979,8,1]],"date-time":"1979-08-01T00:00:00Z","timestamp":302313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[1979,8]]},"abstract":"<jats:p>\n            Studies using\n            <jats:italic>Listeria monocytogenes<\/jats:italic>\n            as an antitumor agent were initiated to determine the requirements for\n            <jats:italic>Listeria<\/jats:italic>\n            -mediated tumor inhibition to occur. When Strain 13 guinea pigs were injected with an admixture of viable\n            <jats:italic>Listeria<\/jats:italic>\n            and a methylcholanthrene-induced fibrosarcoma in a ratio of 1 bacterium to 100 tumor cells,\n            <jats:italic>Listeria<\/jats:italic>\n            had a marked capacity to inhibit tumor growth. This confirms an earlier study in our laboratory (M. M. Dustoor, A. Fulton, W. Croft, and A. A. Blazkovec, Infect. Immun.\n            <jats:bold>23:<\/jats:bold>\n            54-60, 1979). At no time did animals exhibit overt symptoms of disease as a result of\n            <jats:italic>Listeria<\/jats:italic>\n            infection. Animals treated with antilymphocyte serum, which had previously been shown to abrogate T-cell functions, were no longer able to suppress\n            <jats:italic>Listeria<\/jats:italic>\n            -tumor cell mixtures. Treatment in vivo with carrageenan, a macrophage-inhibitory agent, also abrogated\n            <jats:italic>Listeria<\/jats:italic>\n            -mediated tumor inhibition. These results suggest that\n            <jats:italic>Listeria<\/jats:italic>\n            -mediated inhibition requires intact T-lymphocyte and macrophage function. Experiments in which\n            <jats:italic>Listeria<\/jats:italic>\n            was given in admixture with the tumor cells or in the opposite flank demonstrated that the antitumor effects require intimate association of the\n            <jats:italic>Listeria<\/jats:italic>\n            and tumor cells. Histopathological studies, showing that macrophages and lymphocytes are the predominant inflammatory cells present at sites of tumor destruction, further suggest a role for these cells in\n            <jats:italic>Listeria<\/jats:italic>\n            -mediated inhibition. Animals which had rejected prior\n            <jats:italic>Listeria<\/jats:italic>\n            -tumor cell inocula were resistant to rechallenge with the homologous tumor for more than 1 year. This work thus confirms in vitro studies demonstrating that both lymphocytes and macrophages are required for\n            <jats:italic>Listeria<\/jats:italic>\n            -mediated tumor inhibition to occur. This study demonstrates that viable\n            <jats:italic>Listeria<\/jats:italic>\n            can have potent antitumor effects without causing overt disease as a result of\n            <jats:italic>Listeria<\/jats:italic>\n            infection.\n          <\/jats:p>","DOI":"10.1128\/iai.25.2.708-716.1979","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T02:30:46Z","timestamp":1578018646000},"page":"708-716","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Mechanisms of\n            <i>Listeria monocytogenes<\/i>\n            -Mediated Modulation of Tumor Growth"],"prefix":"10.1128","volume":"25","author":[{"given":"Amy M.","family":"Fulton","sequence":"first","affiliation":[{"name":"Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53706"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Croft","sequence":"additional","affiliation":[{"name":"Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53706"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meher M.","family":"Dustoor","sequence":"additional","affiliation":[{"name":"Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin 53706"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Blazkovec","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University of Wisconsin-Madison, Madison, Wisconsin 53706"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/iai.25.2.708-716.1979","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/iai.25.2.708-716.1979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T21:15:32Z","timestamp":1646428532000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/iai.25.2.708-716.1979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1979,8]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1979,8]]}},"alternative-id":["10.1128\/iai.25.2.708-716.1979"],"URL":"https:\/\/doi.org\/10.1128\/iai.25.2.708-716.1979","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[1979,8]]},"assertion":[{"value":"1979-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}